Canada markets closed

AstraZeneca PLC (AZNCF)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
109.66-1.76 (-1.58%)
At close: 03:27PM EST
Full screen
Loading interactive chart...
  • Bloomberg

    AstraZeneca Studies Listing of New Vaccines Division

    (Bloomberg) -- AstraZeneca Plc has been studying options including a potential listing of its newly-created vaccines division as it seeks ways to boost returns for investors, people with knowledge of the matter said. Most Read from BloombergThe Hot New Trend For Hedge Funds Is—Finally—Female Founders‘Ghost Signs’ Haunt London’s Reviving NeighborhoodsReliving the New York Subway Map DebateAutomating the War on Noise Pollution‘Pension Poachers’ Are Targeting America’s Elderly VeteransThe U.K. phar

  • Business Wire

    AstraZeneca Reinforces Leadership in Breast Cancer at SABCS 2021 With New Data Underscoring Ambition to Redefine Cancer Care

    WILMINGTON, Del., December 03, 2021--AstraZeneca will underscore its ambition to redefine care with new data from across its portfolio of innovative medicines at the 2021 San Antonio Breast Cancer Symposium (SABCS) December 7-10, 2021.

  • Reuters

    UPDATE 1-UK study finds mRNA COVID-19 vaccines provide biggest booster impact

    COVID-19 vaccines made by Pfizer and Moderna that use mRNA technology provide the biggest boost to antibody levels when given 10-12 weeks after the second dose, a new British study has found. The "COV-Boost" study was cited by British officials when they announced that Pfizer and Moderna were preferred for use in the country's booster campaign, but the data has only been made publicly available now. The study found that six of the seven boosters examined enhanced immunity after initial vaccination with Pfizer-BioNTech's vaccine, while all seven increased immunity when given after two doses of AstraZeneca's vaccine.